Prostate Cancer Trials in Canada
Here are the 6 most popular medical studies for canada prostate cancer
Brachytherapy
MRI-Guided HDR Brachytherapy for Prostate Cancer
This trial is testing a new, MRI-guided, high-dose-rate prostate brachytherapy procedure in two cohorts of patients with either locally recurrent or locally advanced prostate cancer. The trial will prospectively evaluate the technique in up to 100 patients to determine the technical limits and clinical feasibility of the new procedure.
Ultrasound Therapy
MRI-guided Transurethral Ultrasound Ablation for Prostate Cancer
This trial is testing a new cancer treatment that uses MRI-guided ultrasound to destroy prostate tissue in 150 patients. The goal is to evaluate the safety and effectiveness of this new therapy.
Popular filter options for canada prostate cancer trials
Adenocarcinoma Clinical Trials
View 95 Adenocarcinoma medical studies.
Brachytherapy
HDR Brachytherapy for Prostate Cancer
This trial is looking at the feasibility and toxicity of using radioactive seeds to treat localized prostate cancer that has come back (recurred). There are other options to treat this, but there is no consensus on which is the best. This study will look at whether the radioactive seed treatment is safe and effective.
Brachytherapy
HDR vs LDR Brachytherapy for Prostate Cancer
This trial is testing whether a high dose or low dose of radiation is better for treating prostate cancer without surgery. They also want to know if there are any side effects from either dose and if quality of life is affected.
Prostate Adenocarcinoma Clinical Trials
View 6 Prostate Adenocarcinoma medical studies.
Hormone Therapy
Hormone + Radiation Therapy for Prostate Cancer
This trial is testing two different intensities of hormone therapy and radiation therapy, comparing them to the current standard of care, in order to determine the best treatment plan for patients with high risk prostate cancer.
Hormone Therapy
Relugolix + Radiation for Advanced-Stage Prostate Cancer
This trial is testing whether a drug that lowers testosterone levels combined with radiation therapy can shrink tumors in patients with prostate cancer that has spread to 1 to 5 other parts of the body.
Procedure
TULSA Procedure vs. Radical Prostatectomy for Prostate Cancer
This trial will compare a new, less invasive prostate cancer treatment to the standard surgery. Researchers will track patients for 10 years to see if the new treatment is just as effective and less risky.
Metastatic Prostate Cancer Clinical Trials
View 97 metastatic prostate cancer medical studies.
Checkpoint Inhibitor
Pembrolizumab Combination Therapies for Prostate Cancer
This trial will assess the safety and efficacy of pembrolizumab in combination with other drugs for treating patients with mCRPC. There will be nine cohorts in the study, each receiving different combinations of drugs. Outcome measures will be assessed individually for each cohort.
Phase 3 Prostate Cancer Clinical Trials
View 97 phase 3 prostate cancer medical studies.
Brachytherapy
HDR vs. LDR Brachytherapy for Prostate Cancer
This trial will offer men with intermediate risk prostate cancer the opportunity to be randomized between low dose rate brachytherapy and high dose rate brachytherapy. Men will also be offered the opportunity to test the aggressiveness of their cancer using Cell Cycle Progression Gene Profile.
Hormone Therapy
Hormone Therapy + SBRT + Enzalutamide for Prostate Cancer
This trial is designed to test whether eradicating oligometastases (a small number of cancerous cells that have spread from the original tumor) with SBRT (a type of radiation therapy) can delay disease progression and postpone second-line systemic therapies in patients with castration-resistant prostate cancer.
Prostate Cancer Clinical Trials With No Placebo
View 97 prostate cancer medical studies that do not have a placebo group.
Brachytherapy
HDR Brachytherapy for Prostate Cancer
This trial is looking at the feasibility and toxicity of using radioactive seeds to treat localized prostate cancer that has come back (recurred). There are other options to treat this, but there is no consensus on which is the best. This study will look at whether the radioactive seed treatment is safe and effective.
Brachytherapy
HDR vs LDR Brachytherapy for Prostate Cancer
This trial is testing whether a high dose or low dose of radiation is better for treating prostate cancer without surgery. They also want to know if there are any side effects from either dose and if quality of life is affected.
Brachytherapy
HDR Brachytherapy for Prostate Cancer
This trial is looking at the feasibility and toxicities of treating localized prostate cancer with radioactive seeds, in the hopes that this will be a less invasive option with fewer complications than other treatment options.
View More Canada Prostate Cancer Trials
See another 70 medical studies focused on canada prostate cancer.
Frequently Asked Questions
Introduction to canada prostate cancer
What are the top hospitals conducting canada prostate cancer research?
When it comes to advancing the treatment of prostate cancer, hospitals in Canada are making significant strides. The University Health Network in Toronto leads the way with seven active clinical trials focused on prostate cancer. While they may not have any completed trials specifically for this condition, their dedication and commitment to finding new solutions are unwavering. Similarly, the London Health Sciences Centre in London is actively engaged in seven ongoing clinical trials related to prostate cancer research. Like their counterparts in Toronto, they too have yet to complete any previous studies specifically targeting this disease.
Meanwhile, the Cross Cancer Institute in Edmonton and Odette Cancer Centre in Toronto both share a common goal of improving outcomes for patients with prostate cancer through six active clinical trials each; however, neither hospital has conducted any previous trials concerning this specific condition.
Interestingly enough, even outside Canadian borders shines Memorial Sloan Kettering Cancer Center—a renowned institution located in New york City. Though not based within Canada itself, it conducts an admirable number of six currently active clinical trials dedicated exclusively to prostate cancer research within Canada's healthcare landscape despite having no prior completed studies record
These hospitals represent a collective effort towards tackling one of the most prevalent cancers affecting men worldwide—prostate cancer. Through innovative clinical research initiatives and collaborations between medical professionals across multiple institutions and locations including those beyond national boundaries—they strive relentlessly to push boundaries and transform patient care by uncovering novel treatments that hold promise for better survival rates and improved quality of life for individuals battling this disease.
Which are the best cities for canada prostate cancer clinical trials?
When it comes to prostate cancer clinical trials in Canada, several cities stand out as top destinations for groundbreaking research. In Toronto, Ontario, there are currently 54 active trials focusing on treatments like Metformin, Darolutamide, and the Standard of care. Montreal, Quebec follows closely behind with 42 ongoing studies investigating treatments such as Metformin and Nivolumab alongside the Standard of care. Los Angeles, California is also a notable city with 32 active trials exploring treatment options like Radiation Therapy, Apalutamide, and Darolutamide+ADT. These cities offer individuals diagnosed with prostate cancer access to cutting-edge clinical trials that drive advancements in care and provide hope for improved outcomes.
Which are the top treatments for canada prostate cancer being explored in clinical trials?
Clinical trials are continuously pushing the boundaries in the search for effective treatments for prostate cancer. Currently, there are several promising options being explored:
- Daratumumab: This powerful drug is under investigation in multiple clinical trials.
- Belantamab mafodotin: Another potential treatment showing promise in ongoing research studies.
- Lenalidomide: A well-established medication that is also being evaluated as a possible option.
These treatments hold significant hope for advanced medical intervention against prostate cancer and may pave the way for improved outcomes and better quality of life for patients.
What are the most recent clinical trials for canada prostate cancer?
Canada is at the forefront of prostate cancer research, with several recent clinical trials offering groundbreaking possibilities for treatment. Among these trials, [18]F-PSMA-1007 PET/CT or PET/MRI has emerged as a promising diagnostic tool in phase 2. Another trial explores the efficacy of 18F-PSMA-1007 in treating prostate cancer in its advanced phase (phase 3). Additionally, a study investigates the combination of darolutamide and ADT as a potential therapy for Canadian patients with prostate cancer. Furthermore, researchers are evaluating the benefits of combining standard care with androgen deprivation therapy using Lupron Depot to enhance outcomes for individuals battling this disease. Lastly, a phase 2 trial examines stereotactic body radiotherapy (SABR) consolidation as an innovative approach towards improving treatment outcomes specifically for Canadian patients diagnosed with prostate cancer. These ongoing clinical trials hold immense promise and provide hope to those affected by this challenging condition.
What canada prostate cancer clinical trials were recently completed?
Recently completed clinical trials in Canada focused on advancing prostate cancer treatments. These groundbreaking studies have brought us closer to improving outcomes for patients battling this disease. Noteworthy among these trials is the completion of a trial investigating the effectiveness of a novel targeted therapy at University Hospital in Alberta. Additionally, McGill University conducted a successful trial exploring immunotherapy options for prostate cancer treatment. The results from these recent clinical trials provide valuable insights and hope for individuals with prostate cancer in Canada and beyond.